Retrospective Study
Copyright ©The Author(s) 2020.
World J Gastroenterol. Apr 7, 2020; 26(13): 1501-1512
Published online Apr 7, 2020. doi: 10.3748/wjg.v26.i13.1501
Table 2 Univariate analysis in the derivation cohort
VariablesOverall survival
Recurrence-free survival
HR95%CIP valueHR95%CIP value
Age1.0020.987-1.0170.8190.9980.985-1.0110.763
Gender, F/M0.7520.546-1.0350.080a0.8460.633-1.1320.262
HBsAg1.2100.853-1.7170.2851.2740.924-1.7560.139
Hepatolithiasis1.5931.061-2.3930.025a1.1760.785-1.7610.433
Child-Pugh grade, A /B0.6140.323-1.1670.1360.7320.381-1.3670.317
Ascites1.6391.011-2.6580.045a1.5320.988-2.3760.056a
CA-199 (≥ 22/< 22)0.9530.926-0.9810.001a1.5461.259-1.899< 0.001a
Tumor size1.0751.012-1.1410.019a1.1231.063-1.187< 0.001a
Tumor number, Multiple/Single1.6551.172-2.3280.004a1.8931.388-2.582< 0.001a
Tumor differentiation, Moderate-Poor/Well1.8910.699-5.1150.2093.2771.045-10.2740.042a
Macrovascular invasion1.3710.953-1.9720.089a1.2770.913-1.7870.153
Microvascular invasion1.6191.029-2.5480.037a1.9831.306-3.0120.001a
Liver capsule invasion0.8150.586-1.1340.2251.1400.833-1.5610.412
Node-positive2.8462.030-3.989< 0.001a2.4841.810-3.409< 0.001a
Perineural invasion1.7371.129-2.6730.012a1.2450.821-1.8870.302
Cirrhosis1.5261.094-2.1300.013a1.1820.863-1.6170.297
TNM stage, III/I-II1.0670.745-1.5290.7221.4311.010-2.0280.044a
BCLC, B-C/0-A1.2950.906-1.8500.1561.6071.150-2.2460.005a
NLR, > 2.62/≤ 2.621.7011.221-2.3710.002a1.4221.057-1.9120.020a
PLR, > 103/≤ 1031.3660.983-1.8970.063a1.3601.009-1.8330.043a
GLR, > 33.7/≤ 33.72.3161.617-3.316< 0.001a1.9311.413-2.639< 0.001a